A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study will determine whether the investigational drug dasatinib is effective in
treatment of women with progressive advanced triple-negative breast cancer.